Document ID: chunk:federal_register_of_legislation:F2018L00192:reg:9:p2
Version: federal_register_of_legislation:F2018L00192
Segment Type: reg
Provision Reference: reg 9 (pt 2/2)
Character Range: 6058–7605

of toxic retinopathy;
Note: taking oral canthaxanthin supplements or tablets as specified is defined in the Schedule 1 - Dictionary.
(14)      inhaling isopropyl nitrite within the two weeks before the clinical onset of toxic retinopathy;
(15)      using an intravenous drug containing talc within the five years before the clinical onset of toxic retinopathy;
(16)      for cystoid macular oedema only:
(a)          being treated with daily niacin for a continuous period of at least two weeks, at an average dose of at least 1.5 grams per day, within the three months before the clinical onset of toxic retinopathy;
(b)          being treated with intravenous paclitaxel or docetaxel within the three months before the clinical onset of toxic retinopathy; or
(c)          being treated with the thiazolidinedione drugs rosiglitazone or pioglitazone for a continuous period of at least the four weeks before the clinical onset of toxic retinopathy;
Note: cystoid macular oedema is defined in the Schedule 1 - Dictionary.
(17)      for cystoid macular oedema only, in an aphakic or pseudophakic eye only:
(a)          being treated with topical adrenaline eye drops, within the three months before the clinical onset of toxic retinopathy; or
(b)          being treated with latanoprost within the three months before the clinical onset of toxic retinopathy;
Note: cystoid macular oedema and aphakic or pseudophakic eye are defined in the Schedule 1 - Dictionary.
(18)      inability to obtain appropriate clinical management for toxic retinopathy.